The ELM-PC 5 phase III randomized, double blind, multicentre trial comparing treatment with orteronel plus prednisone with placebo plus prednisone failed to show an overall survival benefit for orteronel therapy. Several possible reasons exist for the lack of a positive result in this study.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Fizazi, K. et al. Phase III, randomized, double-blind, multicenter trial comparing Orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5. J. Clin. Oncol. 33, 723–731 (2015).
Sharifi, N. Mechanisms of androgen receptor activation in castration-resistant prostate cancer. Endocrinology 154, 4010–4017 (2013).
de Bono, J. S. et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364, 1995–2005 (2011).
Ryan, C. J. et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N. Engl. J. Med. 368, 138–148 (2012).
Yamaoka, M. et al. Orteronel (TAK-700), a novel non-steroidal 17, 20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys. J. Steroid Biochem. Mol. Biol. 129, 115–128 (2012).
Dreicer, R. et al. Phase I/II trial of orteronel (TAK-700)—an investigational 17, 20-lyase inhibitor—in patients with metastatic castration-resistant prostate cancer. Clin. Cancer Res. 20, 1335–1344 (2014).
Ryan, C. J. et al. Androgen dynamics and serum PSA in patients treated with abiraterone acetate. Prostate Cancer Prostatic Dis. 17, 192–198 (2014).
Li, R. et al. Abiraterone inhibits 3beta-hydroxysteroid dehydrogenase: a rationale for increasing drug exposure in castration-resistant prostate cancer. Clin. Cancer Res. 18, 3571–3579 (2012).
Richards, J. et al. Interactions of Abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100. Cancer Res. 72, 2176–2182 (2012).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Sharifi, N. CYP17A1 inhibitor failure—lessons for future drug development. Nat Rev Urol 12, 245–246 (2015). https://doi.org/10.1038/nrurol.2015.66
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2015.66
